Synthesis method of phosphamide ester nucleoside prodrug and drug application
Synthesis of new phosphoramidine nucleoside drug prodrug through the phosphoramidine prodrug strategy, solving the problem of nucleoside antiviral drugs carrying negative electrons and nucleoside kinase-dependent in the internal environment, and achieving drug stability and biological stability The improvement in utilization significantly improves the therapeutic effect.
Patent Information
- Application Number
- CN202411071173.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-06
- Publication Date
- 2024-11-19
AI Technical Summary
Existing nucleoside antiviral drugs carry negative electrons in the internal environment and are difficult to enter cells. They rely on endocytosis of the cell membrane. The process of entering cells into active triphosphate metabolites is slow, and the targeting effect is weak, which may cause cytotoxicity. .
Using the phosphoramidate prodrug strategy, the synthesis of phosphorus oxychloride and 2-(hydroxymethyl)phenyl acetate and other raw materials were synthesized through multiple steps such as bromination, hydrolysis, overprotecting group, carbonyl reduction and glycosylation. New phosphamide ester nucleoside drug prodrug avoid dependence on nucleoside kinases, enhance stability, and improve bioavailability.
It effectively avoids dependence on nucleoside kinases, resists metabolic inactivation of phosphohydrolases, improves the stability and bioavailability of drugs, enhances the effect on target cells, and significantly improves the therapeutic effect.
Smart Images

Figure CN118978559A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of organic chemistry, and specifically relates to a method for preparing phosphoramidate nucleoside drug prodrugs and an application thereof. Background Art
[0002] The phosphoramidate prodrug strategy refers to the use of amino acid esters and phenol derivatives to mask the negative charge of phosphate to generate a phosphoramidate structure. This prodrug strategy is also the most successful strategy in the application of nucleoside antiviral drugs so far.
[0003] In the phosphoramidate prodrug strategy, the negative charge of the phosphate group is masked by the aromatic group and the amino acid ester group to be electrically neutral, and then enters the cell through the cell membrane. In the cell, the amino acid ester is first hydrolyzed by esterase to generate a carboxyl group, and then the carboxyl group loses a hydrogen to form an oxygen anion. The oxygen anion attacks the phosphate group by nucleophilic addition, causing the aromatic group to fall and generate an unstable five-membered ring. Then the five-membered ring is hydrolyzed to open the ring to generate an aminophosphoroester metabolite, and finally the PN bond is broken by the action of phosphoramidase (histidine triad nucleotide binding protein 1, HINT-1) to generate an active monophosphate nucleoside drug molecule. Sofosbuvir and tenofovir alafenamide were developed based on this strategy.
[0004] Nucleoside prodrugs designed using the phosphoramidate prodrug strategy have three sites that can be modified: (1) modification of the amino acid ester side chain: the configuration of the amino acid side chain directly affects the activity of the drug. Experiments have shown that the drug activity of L-configuration amino acids is far superior to that of D-configuration amino acids; (2) modification of the amino acid ester group: the introduction of primary alkanes, secondary alkanes or benzyl groups into the ester group makes it easier to be hydrolyzed by esterases; (3) modification of the aromatic group: strong electron-withdrawing groups or halogens can be introduced into the aromatic benzene ring, which not only facilitates the departure of the aromatic group, but also facilitates the nucleophilic attack of the carboxyl group on the phosphate ester to generate a five-membered ring intermediate and release the aminophosphoryl metabolite intermediate.
[0005] At present, nucleoside antiviral drugs have become the mainstream of small molecule broad-spectrum antiviral drugs. As more and more nucleoside antiviral drugs are born and used in practice, some of its shortcomings are gradually revealed. First, because nucleoside antiviral drugs carry negative electrons in the body environment, their entry into cells mainly depends on the endocytosis of the cell membrane, and their concentration is low at the pathogen; secondly, the rate-determining step for nucleoside antiviral drugs to enter the cell and become active triphosphate metabolites is that they are activated by nucleoside kinase to monophosphate intermediates, which is a relatively slow process and slows down their onset of action; finally, because most cells in the human body have nucleoside kinases, nucleoside antiviral drugs have weak targeting effects and may even produce cytotoxicity.
[0006] In view of the above shortcomings of the prior art, the present invention designs and synthesizes a series of novel phosphoramidate nucleoside drug prodrugs through the phosphoramidate prodrug strategy, which effectively avoids the dependence of such drugs on nucleoside kinases, resists the metabolic inactivation of phosphohydrolases, and enhances their stability. It repairs the defect that such drugs are not easy to act on target cells due to their ionic characteristics, improves bioavailability, and greatly improves the therapeutic effect. Summary of the invention
[0007] In order to overcome the above technical defects, the purpose of the present invention is to provide a novel phosphoramidate nucleoside drug prodrug, and study its synthesis method and active application of the compound. Using phosphorus oxychloride and 2-(hydroxymethyl)phenyl acetate as raw materials, adopting multi-step continuous reactions such as bromination, hydrolysis, protective group, carbonyl reduction and glycosylation, a phosphoramidate nucleoside analog containing biological activity is obtained. The method of the present invention adopts a one-pot synthesis, the reaction raw materials are easy to obtain, the synthesis steps are simple, and the reaction conditions are mild. These novel phosphoramidate nucleoside drug prodrugs effectively avoid the dependence of such drugs on nucleoside kinases, resist the metabolic inactivation of phosphohydrolase, enhance their stability, repair the defect that such drugs are not easy to act on target cells due to their ionic characteristics, and improve bioavailability.
[0008] The phosphoramidate nucleoside drug prodrug of the present invention has the following general structural formula:
[0009]
[0010] Wherein: the glycoside is selected from (2'R)-2'-deoxy-2'-fluoro-2'-methyluridine, 5-fluoro-2'-deoxyurea nucleoside, cytarabine, ribavirin, cytidine, stavudine, 2',3'-O-isopropylcytidine, 5-bromocytidine, gemcitabine, zidovudine or lamivudine, and the 5'-hydroxyl group in the glycoside is connected to the phosphorus atom.
[0011] The present invention also provides a method for synthesizing the novel phosphoramidate nucleoside drug prodrug, and the reaction equation is as follows:
[0012]
[0013] Wherein: the glycoside is selected from (2'R)-2'-deoxy-2'-fluoro-2'-methyluridine, 5-fluoro-2'-deoxyurea nucleoside, cytarabine, ribavirin, cytidine, stavudine, 2',3'-O-isopropylcytidine, 5-bromocytidine, gemcitabine, zidovudine or lamivudine, and the 5'-hydroxyl group in the glycoside is connected to the phosphorus atom.
[0014] The method comprises the following steps: using phosphorus oxychloride 1 and 2-(hydroxymethyl)phenyl acetate 2 as raw materials, reacting in an organic solvent in the presence of an organic base to obtain an intermediate 3; then reacting the intermediate 3 with L-alanine isopropyl ester hydrochloride 4 in an organic solvent in the presence of an organic base to obtain an intermediate 5; reacting the intermediate 5 with 4-nitrophenol 6 in an organic solvent in the presence of an organic base to obtain an intermediate 7; and reacting the intermediate 7 with a glycoside 8 in an organic solvent in the presence of a catalyst to obtain a product 9.
[0015] Furthermore, in the first step of the above technical scheme, the organic solvent is selected from dichloromethane, the reaction temperature is selected from -78°C to -60°C, the reaction is carried out in an inert gas, and the molar ratio of compound 1, compound 2 and the organic base is 1:1:1.
[0016] Furthermore, in the second step of the above technical scheme, the organic solvent is selected from dichloromethane, chloroform or 1,2-dichloroethane; the reaction temperature is selected from -78°C to 30°C, the reaction is carried out in an inert gas, and the molar ratio of intermediate 3, L-alanine isopropyl hydrochloride and organic base is 1:1:2.
[0017] Furthermore, in the second step of the above technical scheme, the source of L-alanine isopropyl hydrochloride 4 is: using L-alanine and isopropanol as raw materials, reacting in an organic solvent in the presence of a catalyst thionyl chloride to obtain compound 4.
[0018] Furthermore, in the third step of the above technical scheme, the organic solvent is selected from dichloromethane, chloroform or 1,2-dichloroethane; the reaction temperature is selected from 0-30°C, the reaction is carried out in an inert gas, and the molar ratio of the intermediate 5, 4-nitrophenol to the organic base is 1:0.8:2.
[0019] Furthermore, in the fourth step of the above technical scheme, the organic solvent is selected from DMF and DMSO; the reaction temperature is selected from 0-40°C, the reaction is carried out in an inert gas, and the molar ratio of intermediate 7, glycoside and catalyst is 2:1:2.
[0020] Furthermore, in the first to third steps of the above technical scheme, the organic base is selected from triethylamine, diisopropylethylamine or pyridine; in the fourth step, the catalyst is selected from tert-butylmagnesium chloride.
[0021] The present invention also provides the use of the novel phosphoramidate nucleoside drug prodrug in the preparation of antiviral and anticancer drugs.
[0022] Furthermore, in the above technical solution, the antiviral agent is selected from HepG2 / 2.2.15 cells which can stably and sustainably express HBV virus.
[0023] Furthermore, in the above technical solution, the anticancer is selected from anti-M7, 5637, CFPAC-1, A549 or HepG2.
[0024] The present invention also provides a pharmaceutical composition containing the aforementioned phosphoramidate nucleoside drug prodrug.
[0025] Advantageous Effects of the Invention
[0026] 1. The present invention uses the phosphoramidate prodrug strategy to design and synthesize a series of novel phosphoramidate nucleoside drug prodrugs, which effectively avoids the dependence of such drugs on nucleoside kinases, resists the metabolic inactivation of phosphohydrolases, and enhances their stability. It repairs the defect that such drugs are not easy to act on target cells due to their ionic characteristics, improves bioavailability, and greatly improves the therapeutic effect.
[0027] 2. The novel phosphoramidate nucleoside prodrug of the present invention has a good inhibition rate on 5637 and A549 cells. BRIEF DESCRIPTION OF THE DRAWINGS
[0028] Figure 1 The experimental steps for the biological activity test of the novel phosphoramidate nucleoside drug prodrug in Example 4;
[0029] Figure 2 is the relative expression of HBV DNA in HepG2 / 2.2.15 cells by the novel phosphoramidate nucleoside prodrug in Example 4;
[0030] Figure 3 This is a graph showing the inhibition rate of the novel phosphoramidate nucleoside prodrug on 5637 cells in Example 5 (25 μM);
[0031] Figure 4 This is a graph showing the inhibition rate of the novel phosphoramidate nucleoside prodrug on A549 cells in Example 5 (25 μM);
[0032] Figure 5 This is a graph showing the inhibition rate of the novel phosphoramidate nucleoside prodrug on M7 cells in Example 5 (25 μM);
[0033] Figure 6 This is a graph showing the inhibition rate of the novel phosphoramidate nucleoside prodrug on CFPAC-1 cells in Example 5 (25 μM);
[0034] Figure 7 This is a graph showing the inhibition rate of the novel phosphoramidate nucleoside prodrug on HepG2 cells in Example 5 (25 μM). Specific embodiments
[0035] The present invention will be further described below by specific examples. These embodiments should be understood to be only used to illustrate the present invention and not to limit the scope of protection of the present invention. After reading the content of the present invention, those skilled in the art may make various changes or modifications to the present invention, and these equivalent changes and modifications also fall within the scope defined by the claims of the present invention.
[0036] Example 1
[0037]
[0038]
[0039] Under anhydrous and nitrogen atmosphere, add 120mL of ultra-dry dichloromethane to a 250mL two-necked bottle with three-way, place it in a -78℃ cold trap, wait until the solution temperature drops to -78℃, add compound 2 (8.31g, 50mmol) and ultra-dry triethylamine (6.95mL, 50mmol) to the solution, then add compound 1 (4.66mL, 50mmol) dropwise, react at -78℃ for 4 hours, and monitor the reaction by TLC. After the reaction of compound 2 is complete, add compound 4 (8.38g, 50mmol) to the above reaction solution, stir at -78℃ for 15 minutes, add ultra-dry triethylamine (13.90mL, 100mmol), continue stirring for 1 hour, and then move the reaction solution to room temperature and stir for 2 hours. The reaction mixture was placed in an ice-water bath and cooled to 0°C. Super dry triethylamine (13.90 mL, 100 mmol) was first added to the reaction solution, and then 4-nitrophenol (5.56 g, 40 mmol) was added in small amounts and multiple times. The reaction solution was then moved to room temperature and stirred overnight. After TLC monitoring of the reaction was complete, the reaction system was cooled in an ice-water bath, and 100 mL of saturated ammonium chloride was quickly added dropwise while stirring to quench the reaction. The organic phase was separated, and the aqueous phase was extracted with dichloromethane (20 mL × 3). The organic phases were combined, washed with saturated ammonium chloride (80 mL), purified water (80 mL × 2), and saturated sodium chloride (80 mL). The organic phase was dried over anhydrous sodium sulfate, concentrated, and separated by silica gel column chromatography. The eluent was petroleum ether / ethyl acetate (30:1-3:1) to separate the colorless semi-solid product. The colorless semi-solid was slurried with isopropanol / n-hexane (1:4) to obtain 9.95 g of white solid YL-1, with a total yield of 51.8% in three steps. 11H NMR (400 MHz, DMSO-d6) δ 8.37 - 8.23 (m, 2H), 7.53 - 7.35 (m, 5H), 7.28 - 7.18 (m, 1H), 6.85 - 6.70 (m, 1H), 5.11 - 4.98 (m, 2H), 4.90 - 4.75 (m, 1H), 4.02 - 3.87 (m, 1H), 2.02 (d, J = 5.7 Hz, 3H), 1.24 (dd, J = 7.0, 1.3 Hz, 3H), 1.14 - 1.07 (m, 6H). 13 13C NMR (101 MHz, DMSO-d6) δ 172.7 (d, J = 5.0 Hz), 172.6 (d, J = 3.0 Hz), 170.5 (d, J = 3.0 Hz), 155.9 (d, J = 7.0 Hz), 155.8 (d, J = 7.0 Hz), 149.0 (d, J = 7.0 Hz), 148.9 (d, J = 7.0 Hz), 144.6 (d, J = 4.0 Hz), 130.7 (d, J = 24.0 Hz), 130.1 (d, J = 9.0 Hz), 127.6 (d, J = 7.0 Hz), 127.5 (d, J = 7.0 Hz), 126.3, 125.6, 121.6 (d, J = 5.0 Hz), 121.5 (d, J = 5.0 Hz), 120.2 (d, J = 3.0 Hz), 68.7, 61.1 (d, J = 16.0 Hz), 50.5, 21.8, 21.0, 20.0 (d, J = 7.0 Hz). 31 31P NMR (162 MHz, DMSO-d6) δ -1.61, -1.79. HRMS (ESI) m / z: [M+Na] + Calcd for C 21 H 25 N2O9PNa 503.1189; Found 503.1188.
[0040] Example 2
[0041]
[0042] The 10mL Schlenk tube was evacuated 3 times on a double row, heated with a baking gun, and a small magnetic particle was placed in the aerated state while it was hot, and the small magnetic particle was dried with residual heat, and then evacuated 3 times, and the aeration was maintained for 1 hour. Compound YL-1 (0.4mmol) and 5-fluoro-2'-deoxyuridine (0.2mmol) were placed in the Schlenk tube under aeration, and then ultra-dry N,N-dimethylformamide (2.5mL) was added, stirred evenly, and the aeration state was maintained for 2 hours. It was moved to an ice-water bath, and when the temperature of the solution dropped, 0.4mL of tert-butylmagnesium chloride (1M in THF, 0.4mmol) was slowly added to the solution under aeration, and the lid was covered and stirred in an ice-water bath for half an hour, and then moved to a 40℃ sand bath for reaction for 3.5 days. Add 3 mL of ethyl acetate and 3 mL of saturated ammonium chloride solution to the Schlenk tube for quenching, separate the organic phase, extract the aqueous phase with ethyl acetate (10 mL × 3), combine the organic phases, wash with saturated ammonium chloride solution (20 mL), purified water (20 mL × 2), and saturated sodium chloride solution (20 mL), dry over anhydrous sodium sulfate, concentrate the organic phase under reduced pressure, separate by silica gel column chromatography, eluent is dichloromethane / methanol (100-20 / 1), to obtain product C-3.
[0043] A series of compounds were synthesized using the same method as above, and the results are as follows:
[0044]
[0045] Representative characterization data are as follows:
[0046] Compound C-2; 2% yield; 1 H NMR (400MHz, DMSO-d6) δ7.51-7.28(m,6H),7.24-7.13(m,1H),6.41(dd,J=18.8,6.4Hz,1H),6.22-6.13(m,2H),5.80-5.67(m,1H),5.16-5.08(m,2 H),4.88-4.82(m,1H),4.41-4.08(m,3H),4.06-3.96(m,1H),3.84-3.76( m,1H),2.05(d,1.2Hz,3H),1.23(dd,7.3,2.7Hz,3H),1.16-0.85(m,6H). 1313C NMR (101 MHz, DMSO-d6) δ 172.6 (d, 4.0 Hz), 172.5 (d, 5.0 Hz), 170.2, 165.6, 154.5, 148.9 (d, 7.0 Hz), 148.8 (d, 7.0 Hz), 141.0, 130.1, 129.8, 129.4 (d, 11.0 Hz), 127.1 (d, 7.0 Hz), 127.0 (d, 6.0 Hz), 124.6, 122.6, 119.8 (d, 2.0 Hz), 94.8 (d, 5.0 Hz), 78.2, 69.6, 68.1, 64.5, 60.8 (d, 14.0 Hz), 49.8 (d, 14.0 Hz), 21.4, 20.6 (d, 4.0 Hz), 19.7 (d, 6.0 Hz), 19.6 (d, 7.0 Hz). 19 19F NMR (377 MHz, DMSO-d6) δ -115.56 (d, 230.1 Hz), -116.60. 31 31P NMR (162 MHz, DMSO-d6) δ 3.75. HRMS (ESI) m / z: [M+Na] + Calcd for C 24 H 31 F2N4O 10 PNa 627.1638; Found 627.1638.
[0047] Compound C-3; 4% yield; 1 1H NMR (400 MHz, DMSO-d6) δ 7.64 (dd, 11.5, 7.5 Hz, 1H), 7.46 - 7.12 (m, 6H), 6.26 - 6.08 (m, 2H), 5.70 (dd, 7.5, 6.2 Hz, 1H), 5.39 - 5.33 (m, 1H), 5.18 - 5.03 (m, 2H), 4.90 - 4.81 (m, 1H), 4.35 - 4.18 (m, 2H), 3.89 - 3.72 (m, 1H), 3.43 - 3.36 (m, 1H), 3.05 - 2.97 (m, 1H), 2.06 (s, 3H), 1.23 (dd, 7.2, 2.5 Hz, 3H), 1.19 - 1.09 (m, 6H). 1313C NMR (101 MHz, DMSO-d6) δ 172.7 (d, 4.0 Hz), 172.5 (d, 6.0 Hz), 170.2, 165.6, 154.6, 149.0 (d, 6.0 Hz), 148.8 (d, 6.0 Hz), 140.5, 130.1, 129.8, 129.4 (d, 8.0 Hz), 127.2 (d, 6.0 Hz), 126.9 (d, 6.0 Hz), 124.6 (d, 12.0 Hz), 119.9 (d, 3.0 Hz), 119.6 (d, 3.0 Hz), 94.4 (d, 5.0 Hz), 87.0, 81.4 (d, 9.0 Hz), 81.3 (d, 9.0 Hz), 68.1, 67.0 (d, 5.0 Hz), 66.9 (d, 6.0 Hz), 60.8 (d, 16.0 Hz), 49.8 (d, 18.0 Hz), 35.4 (d, 15.0 Hz), 21.3 (d, 3.0 Hz), 20.6, 19.7 (d, 6.0 Hz), 19.6 (d, 7.0 Hz). 31 31P NMR (162 MHz, DMSO-d6) δ 3.66, 3.24. HRMS (ESI) m / z: [M+Na] + Calcd for C 23 H 31 N4O9PSNa 593.1441; Found 593.1441.
[0048] Compound C-9; 3% yield; 1 1H NMR (400 MHz, DMSO-d6) δ 11.86 (s, 1H), 7.87 (dd, 6.9, 4.3 Hz, 1H), 7.41 - 7.37 (m, 2H), 7.33 (td, 7.6, 1.6 Hz, 1H), 7.20 - 7.16 (m, 1H), 6.17 - 6.08 (m, 2H), 5.42 (dd, 13.2, 4.4 Hz, 1H), 5.11 (dd, 17.6, 13.2 Hz, 2H), 4.89 - 4.81 (m, 1H), 4.28 - 4.08 (m, 3H), 3.98 - 3.92 (m, 1H), 3.83 - 3.75 (m, 1H), 2.12 - 2.06 (m, 2H), 2.05 (s, 3H), 1.22 (d, J 7.2, Hz, 3H), 1.16 - 1.11 (m, 6H). 13C NMR(101MHz,DMSO-d6)δ172.7(d,4.0Hz),172.5(d,6.0Hz),170.20,157.0(d,26.0Hz),149.0,148.9(d,6.0Hz),148.8 (d,6.0Hz),141.2(d,3.0Hz),138.9(d,3.0Hz),129.8(d,31.0Hz),129.4(d,12.0Hz),127.1(d,6.0Hz),127.0(d,7.0Hz ),124.7(d,16.0Hz),124.5,124.4(d,16.0Hz),119.8(d,2.0Hz),119.7(d,2.0Hz),84.7(d,4.0Hz),84.6(d,4.0Hz),8 4.5(d,4.0Hz),70.1,68.1,66.0(t,5.0Hz),60.8(d,13.0Hz),49.9(d,14.0Hz),21.3(d,4.0Hz),20.6,19.7(d,7.0Hz). 19 F NMR(377MHz,DMSO-d6)δ-166.53,-166.64. 31 P NMR(162MHz,DMSO-d6)δ3.98,3.83.HRMS(ESI)m / z:[M+Na] + Calcdfor C 24 H 31 F3O 11 PNa 610.1572; Found 610.1576.
[0049] Example 4
[0050] This example is the detection process and results of the inhibition of HBV virus replication in cells by the compounds described in Example 1. The materials and consumables listed in this example can be obtained from commercial channels unless otherwise specified, and the cells and viruses are from the cell and microbial resource library of CTCC or other relevant institutions. The experimental method of this example is a standard molecular biology, cell biology or virology operating procedure, which can be easily understood and operated by researchers in the field. The specific steps are as follows:
[0051] 1. Cells:
[0052] HepG2 / 2.2.15 (HBV ayw inserted, D subtype, 3182 bp, stable expression), culture conditions: DMEM+10% FBS+1% (strep++pen+)+380 μg / ml G418+0.2% L-Glutamine+0.2% non-essential amino acids.
[0053] Note: HBV DNA is carried by these cells as chromosomally integrated sequences and episomally as relaxed circular, covalently closed, and incomplete copies of the HBV genome. The majority of HBV DNA appears to be present in the form of covalently closed circular (ccc) and nicked recircularized forms, as well as incomplete copies of the genome.
[0054] 2. Main reagents:
[0055] DMEM (Gibco, cat:C11995500BT);
[0056] Fetal bovine serum FBS (Gibco, cat: 10270-106);
[0057] Double Pen-Strep (10,000U / mL) (M&C gene biotechnology, cat: G2723M3);
[0058] Anti-HBV positive drugs: 3TC (lamivudine; donated by Academician Chang Junbiao);
[0059] Tguide Smart Universal Genomic DNA Extraction Kit (TIANGEN, mat: 4995051)
[0060] 3. Experimental steps: ( Figure 1 )
[0061] Step 1: Preliminary screening of compounds for inhibition of HBV activity:
[0062] The experiment set up two control groups, namely: ① positive drug group: add the final concentration of 50
[0063] μM 3TC; ② Virus control group: only DMSO was added without compound.
[0064] Step 2, HepG2 / 2.2.15 cells, 1x 105 cells / well, 12-well plate, 750 μL / well.
[0065] Step 3: 12-16 h after the cells are completely attached, add 750 μL DMEM and 1.5 μL of the compound to be tested (5 mM), and the final concentration of the compound is 5 μM.
[0066] Step 4: On the 4th day of culturing at 37°C, supplement with 250 μL of culture medium containing 5 μM of the compound to be tested.
[0067] Step 5: On the sixth day of culturing at 37°C, supplement with 250 μL of culture medium containing 5 μM of the compound to be tested.
[0068] Step 6: On the 8th day of culturing at 37°C, collect the cells and culture supernatant.
[0069] Step 7: Extract the sample DNA using an automatic nucleic acid extractor, and determine the inhibition rate of the compound on HBV virus using the qPCR method (real-time fluorescence quantitative polymerase chain reaction).
[0070] Supplement: qPCR detection:
[0071] Primer: F Primer: 5'-CCTAGTAGTCAGTTATGTCAAC-3'
[0072] R Primer:5'-TCTATAAGCTGGAGGAGTGCGA-3'
[0073] Amplified gene: C gene
[0074] Amplification conditions: 95°C, 10 min;
[0075] 95℃, 15s; 60℃, 30s; 72℃, 30s×40
[0076] 4. Test results:
[0077] Initial screening of anti-HBV activity at a single concentration (5 μM) Figure 2 )
[0078] (Compound concentration: 5 μM)
[0079] (Control drug 3TC concentration: 50μM)
[0080] Conclusion: At a concentration of 5 μM, the difference between the HBV DNA expression of C-3 compound and the DMSO control group reached a very significant level. The relative expression of HBV DNA of C-3 reached 12.7%, and the inhibitory effect on DNA replication was extremely significant. Figure 2 )
[0081] Example 5
[0082] Nucleoside derivatives have shown significant activity in the anti-tumor field. The CCK-8 assay was used to evaluate the in vitro cytotoxic activity of novel phosphoramidate nucleoside prodrugs against human breast cancer (M7), human bladder cancer cells (5637), pancreatic ductal adenocarcinoma cells (CFPAC-1), human lung cancer cells (A549), and human liver cancer cells (HepG2). Figure 3-7The initial screening results show that at a concentration of 25 μM, C-9 has an inhibition rate of 61.6% on human bladder cancer cells, C-2 has an inhibition rate of 52.8% on human lung cancer cells, and the compounds also have a certain inhibition rate on other cancer cells. This shows that this type of nucleoside drug can be used as a potential anticancer drug for further structural modification and transformation as a prodrug.
[0083] The above description is only a preferred specific implementation manner of the present invention, but the protection scope of the present invention is not limited thereto. Any technician familiar with the technical field can make equivalent replacements or changes according to the technical scheme and inventive concept of the present invention within the technical scope disclosed by the present invention, which should be covered by the protection scope of the present invention.
Claims
1. Phosphamide nucleoside drug prodrug, the general structural formula of which is as follows: in: The glycoside is selected from (2'R)-2'-deoxy-2'-fluoro-2'-methyluridine, 5-fluoro-2'-deoxyuridine, cytarabine, ribavirin, cytidine, stavudine, 2',3'-O-isopropylidene cytidine, 5-bromocytidine, gemcitabine, zidovudine or lamivudine, and the 5'-hydroxyl group in the glycoside is connected to the phosphorus atom.
2. The method for synthesizing a phosphoramidate nucleoside prodrug according to claim 1, wherein: The method comprises the following steps: using phosphorus oxychloride 1 and 2-(hydroxymethyl)phenyl acetate 2 as raw materials, reacting in an organic solvent in the presence of an organic base to obtain an intermediate 3; then reacting the intermediate 3 with L-alanine isopropyl ester hydrochloride 4 in an organic solvent in the presence of an organic base to obtain an intermediate 5; reacting the intermediate 5 with 4-nitrophenol 6 in an organic solvent in the presence of an organic base to obtain an intermediate 7; and reacting the intermediate 7 with a glycoside 8 in an organic solvent in the presence of a catalyst to obtain a product 9. The reaction equation is as follows: Wherein: the glycoside is selected from (2'R)-2'-deoxy-2'-fluoro-2'-methyluridine, 5-fluoro-2'-deoxyurea nucleoside, cytarabine, ribavirin, cytidine, stavudine, 2',3'-O-isopropylidene cytidine, 5-bromocytidine, gemcitabine, zidovudine or lamivudine, and the 5'-hydroxyl group in the glycoside is connected to the phosphorus atom.
3. The method for synthesizing the phosphoramidate nucleoside prodrug according to claim 2, characterized in that: In the first step, the organic solvent is selected from dichloromethane, chloroform or 1,2-dichloroethane, the reaction temperature is selected from -78°C to -60°C, the reaction is carried out in an inert gas, and the molar ratio of compound 1, compound 2 and the organic base is 1:1:1; in the second step, the organic solvent is selected from dichloromethane, chloroform or 1,2-dichloroethane; the reaction temperature is selected from -78°C to 30°C, the reaction is carried out in an inert gas, and the molar ratio of intermediate 3, L-alanine isopropyl ester hydrochloride and the organic base is 1:1:
2.
4. The method for synthesizing the phosphoramidate nucleoside prodrug according to claim 2, wherein: In the third step, the organic solvent is selected from dichloromethane, chloroform or 1,2-dichloroethane; the reaction temperature is selected from 0-30°C, the reaction is carried out in an inert gas, and the molar ratio of intermediate 5, 4-nitrophenol and organic base is 1:0.8:2; in the fourth step, the organic solvent is selected from DMF or DMSO; the reaction temperature is selected from 0-40°C, the reaction is carried out in an inert gas, and the molar ratio of intermediate 7, glycoside and tert-butylmagnesium chloride is 2:1:
2.
5. The method for synthesizing the phosphoramidate nucleoside prodrug according to claim 2, characterized in that: In the first to third steps, the organic base is selected from triethylamine, diisopropylethylamine or pyridine; in the fourth step, the catalyst is selected from tert-butylmagnesium chloride.
6. Use of the phosphoramidate nucleoside prodrug according to claim 1 in the preparation of anticancer drugs.
7. Use of the phosphoramidate nucleoside prodrug according to claim 6 in the preparation of anticancer drugs, characterized in that: The anticancer is selected from anti-M7, 5637, CFPAC-1, A549 or HepG2.
8. Use of the phosphoramidate nucleoside prodrug according to claim 1 in the preparation of antiviral drugs.
9. Use of the phosphoramidate nucleoside prodrug according to claim 8 in the preparation of antiviral drugs, characterized in that: The antiviral agent is selected from HepG2 / 2.2.15 cells that can stably and sustainably express HBV virus.
10. A pharmaceutical composition comprising the phosphoramidate nucleoside prodrug according to claim 1.
